Dug this up from the 2018 10K. Seems like the company is great when it comes to talking with investors but terrible when it comes to execution. 9 months ended September revenues at $14mm, margins at 58%, and negative growth:
OUR STRATEGY In January 2019, the Board of Directors approved our strategic plan to become the preferred drug delivery partner for specific infusion therapies in select markets.
The financial goals for our strategic plan through 2022 are: • $50 million net revenue run rate • 70%+ gross margins, and • 20%+ annual organic revenue growth
We are committed to delivering simple, effective, drug delivery systems to the home health care environment. We believe our Freedom Infusion Systems using DynEqTM technology is superbly positioned for Immunoglobulin therapy and we plan to build on that platform. We plan to drive revenue by supporting the accelerating adoption of Hizentra®, Cuvitru® and other formulations for immunoglobulin therapy and participating in the migration of other therapeutics into the home health marketplace globally. We expect to leverage our specialty pharmacy customer base by bringing additional products and services to our channel.
Market Data 
Markets 
AI
